SCHEMBL309109

SCHEMBL309109

CC(C)(C)OC(=O)N1CCCC(CCN)C1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
BACE1 P56817 2/20 0.51
CTSD P07339 1/20 0.51
GLS O94925 2/20 0.47
HPGD P15428 1/20 0.47
CYP2C9 P11712 1/20 0.46
SCN9A Q15858 1/20 0.46
ACKR3 P25106 1/20 0.46
NR1H2 P55055 1/20 0.44
FPR3 P25089 1/20 0.44
FPR2 P25090 1/20 0.44
FEN1 P39748 2/20 0.44
KDM1A O60341 1/20 0.44
ALOX5AP P20292 1/20 0.42
EPHX1 P07099 1/20 0.42
CHEK2 O96017 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31420749 1.00 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL30924500 1.00 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL31420851 0.96 BACE1 (0.50) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL31420849 0.96 BACE1 (0.50) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL3965741 0.92 MEN1 (0.50) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL16469685 0.91 NR1H2 (0.47) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL1994758 0.91 NR1H2 (0.47) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL30924502 0.91 NR1H2 (0.47) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL31511585 0.91 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL20660178 0.90 HPGD (0.55) MEN1ALDH1A1MAPTKMT2ABACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3638678-B1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX INC (US) 2025-12-03 EP disclosed
EP-4036079-B1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX INC (US) 2025-11-19 EP disclosed
US-20250270191-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-08-28 US disclosed
US-12396961-B2 Compounds and compositions for intracellular delivery of agents MODERNATX, INC. (US) 2025-08-26 US disclosed
EP-4536649-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 EP disclosed
CN-119490487-A Polysubstituted tetrahydrocarbazole compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2025-02-21 CN disclosed
EP-3394030-B2 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX INC (US) 2025-02-12 EP disclosed
US-12077501-B2 Compounds and compositions for intracellular delivery of agents MODERNATX, INC. (US) 2024-09-03 US disclosed
WO-2023244918-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-21 WO disclosed
EP-4036079-A2 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS ModernaTX, Inc. (US) 2022-08-03 EP disclosed
EP-2176247-A2 DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR Amgen Inc. (US) 2010-04-21 EP disclosed
US-20100041645-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 US disclosed
US-20100041645-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 US disclosed
US-20100041645-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 US disclosed
EP-2114869-A1 RHO KINASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2009-11-11 EP disclosed
CN-101448822-A Substituted pyrazolopyrimidines KYOCERA CORP (US) 2009-06-03 CN disclosed
WO-2009009122-A2 DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR AMGEN INC. (US) 2009-01-15 WO disclosed
WO-2008086047-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-17 WO disclosed
WO-2008086047-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-17 WO disclosed
US-20070281949-A1 Substituted pyrazolopyrimidines CEPHALON, INC. (US) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12396961-B2 Compounds and compositions for intracellular delivery of agents LNPK, PLTP, PHOSPHO1 MEN1 3551/4885ALDH1A1 4687/4885MAPT 2543/4885
US-20250270191-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR MEN1 1552/4885ALDH1A1 291/4885MAPT 4449/4885
US-20100041645-A1 RHO KINASE INHIBITORS CIT, ROCK1, RHOT2 MEN1 1736/4885ALDH1A1 3661/4885MAPT 395/4885
US-20070281949-A1 Substituted pyrazolopyrimidines DPYD, P2RX5, P2RX6 MEN1 3595/4885ALDH1A1 813/4885MAPT 491/4885
US-12077501-B2 Compounds and compositions for intracellular delivery of agents LNPK, PLTP, PHOSPHO1 MEN1 3551/4885ALDH1A1 4687/4885MAPT 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.